Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis

References

• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360.
   PubMed Web of Science ®Google Scholar
• Vaid M, Kaur S, Sambatakou H, et al. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007; 45: 183–186.
   PubMed Web of Science ®Google Scholar
• Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37: 865–872.
   PubMed Web of Science ®Google Scholar
• Ohba H, Miwa S, Shirai M, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012; 106: 724–729.
   Google Scholar
• Izumikawa K, Yamamoto Y, Mihara T, et al. Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol 2012; 50: 811–817.
   PubMed Web of Science ®Google Scholar
• Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012; 31: 3231–3239.
   PubMed Web of Science ®Google Scholar
• Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131: 1435–1441.
   PubMed Web of Science ®Google Scholar
• Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Inf Dis 2010; 14: e479–482.
   PubMed Web of Science ®Google Scholar
• Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Inf Dis 2003; 37(Suppl. 3): S265–280.
   Web of Science ®Google Scholar
• Zmeili OS, Soubani AO. Pulmonary aspergillosis: a clinical update. QJM 2007; 100: 317–334.
   PubMed Web of Science ®Google Scholar
• Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open- label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372–379.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee SO, Choi SH, et al. Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. Clin Infect Dis 2011; 52: e149–152.
   PubMed Web of Science ®Google Scholar
• Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896–902.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405–410.
   PubMed Web of Science ®Google Scholar
• De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982–1987). Mycoses 1988; 31: 476–485.
   PubMed Web of Science ®Google Scholar
• Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607–614.
   PubMed Web of Science ®Google Scholar
• Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71: 25–30.
   PubMed Web of Science ®Google Scholar
• Elliott JA, Milne LJ, Cumming D. Chronic necrotising pulmonary aspergillosis treated with itraconazole. Thorax 1989; 44: 820–821.
   Google Scholar
• Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991; 46: 839–841.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kurashima A, Kamei K, et al. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. J Inf Chemother 2012; 18: 378–385.
   PubMed Web of Science ®Google Scholar
• Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002; 121: 1988–1999.
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Fukuda M, Yoshida K, et al. Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. Respirology 2006; 11: 809–813.
   Google Scholar
• Koh WJ, Yu CM, Suh GY, et al. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int J Tuberc Lung Dis 2006; 10: 1001–1007.
   Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
   PubMed Web of Science ®Google Scholar
• Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14: 165–174.
   PubMed Web of Science ®Google Scholar